Polymorphisms of the XXXX and @entity6785 genes in @entity1 with @entity1985 .

@entity1 @entity1262 @entity18597 @entity18595 @entity13842 @entity40609 @entity7656 @entity628 @entity6785 @entity740 @entity134 @entity18599 @entity1985 @entity18598 @entity18596
Oral @entity134 treatment is the first line of therapy for childhood @entity1985 ( @entity1985 ). Nonetheless, some @entity1 are resistant to this treatment. Many efforts have been made to explain the differences in the response to @entity134 treatment in @entity1 with @entity1985 based on the genetic background. We have investigated single nucleotide polymorphisms of the @entity1262 [ @entity7656 ( @entity18595 ), @entity18596 ( @entity18597 ), and @entity18598 ( @entity18599 )] and @entity6785 ( @entity13842 , @entity40609 ) genes in 170 @entity1 with @entity1985 . Of these @entity1 , 69 (40.6%) were initial @entity134 non-responders, and 23 (13.5% of total) developed @entity740 . Renal biopsy findings, which were available for 101 @entity1 , showed that 35 @entity1 had minimal change lesion and 66 had @entity628 . The frequencies of the @entity1262 1236 CC (18.8 vs 7.2%) or TC (53.5 vs 43.5%) genotype and C allele (45.5 vs 29.0%) were significantly higher in the initial @entity134 responders than in the non-responders. Analysis of @entity1262 three-marker haplotypes revealed that the frequency of the TGC haplotype was significantly lower in the initial @entity134 responders than in the non-responders (15.8 vs 29.0%). There was no association between the @entity6785 @entity13842 polymorphism and clinical parameters, renal histological findings, and @entity134 responsiveness. These data suggest that the initial @entity134 response in @entity1 with @entity1985 may be influenced by genetic variations in the @entity1262 gene.
